Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humanigen, Inc. - Common Stock (NQ:HGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Humanigen, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Humanigen, Inc. (HGEN) Investors of Class Action and Encourages Investors to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
HGEN Shareholder Update: Robbins LLP Reminds Investors of Class Action Filed Against Humanigen, Inc. (HGEN)
From Robbins LLP
Via Business Wire
HUMANIGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humanigen, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Humanigen, Inc. Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Humanigen, Inc. (HGEN)
From Robbins LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Humanigen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – HGEN
From Rosen Law Firm
Via Business Wire
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
NASDAQ:HGEN Shareholder Notice: Investigation over Possible Securities Laws Violations by Humanigen, Inc.
San Diego, CA -- (SBWIRE) -- 08/17/2022 -- Humanigen, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Humanigen Reports Second Quarter 2022 Financial Results
From Humanigen, Inc.
Via Business Wire
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused... 
Via Newsfile
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
From Humanigen, Inc.
Via Business Wire
NIH/NIAID Locks ACTIV-5/BET-B Database
From Humanigen, Inc.
Via Business Wire
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in June
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference
From Humanigen, Inc.
Via Business Wire
Humanigen Reports First Quarter 2022 Financial Results
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in May
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
From Humanigen, Inc.
Via Business Wire
Humanigen to Present and Participate at Multiple Investor Events in March
From Humanigen, Inc.
Via Business Wire
Humanigen to Present at BIO CEO & Investor Conference
From Humanigen, Inc.
Via Business Wire
Humanigen Launches Managed Access Program for Lenzilumab
From Humanigen, Inc.
Via Business Wire
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
From Humanigen, Inc.
Via Business Wire
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
From Humanigen, Inc.
Via Business Wire
Humanigen to Present at Investor Conferences January 7 and 13, 2022
From Humanigen, Inc.
Via Business Wire
Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
From Humanigen, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.